TLDR: PhaseV, a prominent leader in applying AI and machine learning to clinical development, has been honored with three significant industry awards in 2025. The company was named to CB Insights’ Digital Health 50 list, TechCrunch’s AI Disruptors 60 list, and received the BioTech Breakthrough ‘Analytics Solution of the Year’ award. These accolades underscore PhaseV’s growing market influence and the impactful adoption of its AI-driven platform in optimizing clinical development processes.
BOSTON, November 6, 2025 – PhaseV, a pioneering force in leveraging artificial intelligence and machine learning for clinical development, today announced it has garnered three prestigious industry awards for 2025. These honors highlight the company’s significant market traction and the increasing adoption of its platform designed to optimize clinical development.
PhaseV was recognized by CB Insights, securing a spot on its Digital Health 50 list, which identifies the most promising private companies in digital health within the Drug Discovery and Development category. Concurrently, the company was included in TechCrunch’s exclusive AI Disruptors 60 list, acknowledging its innovative contributions to the AI landscape. Further solidifying its industry leadership, PhaseV’s platform was distinguished as the ‘Analytics Solution of the Year’ by BioTech Breakthrough, a program that celebrates innovation in biopharma, bioinformatics, and AI-powered analytics.
The core of PhaseV’s success lies in its advanced AI-driven platform, which delivers substantial value to clinical sponsors. The platform is engineered to accelerate drug pipelines, significantly reducing trial costs by up to 50% and speeding up execution timelines by as much as 40%. Crucially, it boasts an impressive capability to improve the probability of success (PoS) for clinical trials by over 30%, thereby unlocking billions of dollars in asset value that might otherwise be missed. The technology is built upon a proprietary data lake, integrating over two million patient-level records and supporting more than 20 predictive disease models across a diverse range of therapeutic areas.
PhaseV’s innovative solutions have earned the trust of over 40 global sponsors, including seven of the world’s leading pharmaceutical companies.
Raviv Pryluk, PhD, CEO and Co-founder of PhaseV, expressed his enthusiasm regarding the recognition: “It’s fantastic to see our team’s dedication recognized with these honors. PhaseV is demonstrating the immediate, tangible value of AI in clinical development, moving beyond the hype to deliver real ROI for pharma. Our investors, partners, and customers are seeing the tangible impact of our platform through smarter trials, faster approvals, and better outcomes for patients. These awards validate the strong momentum we’re building as both a market disruptor and an industry leader.”
Also Read:
- AI in Drug Discovery and Development Market Poised for Significant Growth, Projected to Reach US$34.05 Billion by 2033
- NIH Grant of $2 Million Accelerates AI-Powered Gene Editing for Disease Cures
The selection criteria for these awards often emphasize AI as a core product lever, market traction, and clear disruptive potential, underscoring PhaseV’s impactful role in transforming the future of clinical research.
